3-hydroxykynurenine has been researched along with Inflammation in 17 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether functional vitamin B-6 insufficiency occurs in OC users and is attributable to OCs, we investigated the associations of PLP with metabolites of one-carbon metabolism, tryptophan catabolism, and inflammation in OC users, and evaluated the effects of OCs on these metabolites." | 9.20 | Metabolite profile analysis reveals association of vitamin B-6 with metabolites related to one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in oral contraceptive users and reveals the effects of oral contraceptives o ( Chi, YY; Coats, B; Gregory, JF; Midttun, Ø; Rios-Avila, L; Stacpoole, PW; Ueland, PM, 2015) |
| "PLP is associated with biomarkers of one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in OC users." | 9.20 | Metabolite profile analysis reveals association of vitamin B-6 with metabolites related to one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in oral contraceptive users and reveals the effects of oral contraceptives o ( Chi, YY; Coats, B; Gregory, JF; Midttun, Ø; Rios-Avila, L; Stacpoole, PW; Ueland, PM, 2015) |
| " In plasma from 3035 patients undergoing coronary angiography for suspected coronary heart disease, we investigated if plasma concentrations of any metabolites in the kynurenine pathway, which depend on PLP as cofactor, may serve as metabolic marker(s) of vitamin B-6 status." | 7.77 | Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. ( Bleie, O; Ebbing, M; Midttun, O; Nilsen, RM; Nygård, O; Ringdal Pedersen, E; Schartum-Hansen, H; Ueland, PM; Ulvik, A, 2011) |
| "Increased oxidative stress (SOX), inflammation and prevalence of cardiovascular disease (CVD) have been reported in end-stage renal disease (ESRD), but their associations with kynurenine (KYN) pathway activation remain unknown." | 7.75 | The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. ( Domaniewski, T; Mysliwiec, M; Pawlak, D; Pawlak, K, 2009) |
| "To determine whether functional vitamin B-6 insufficiency occurs in OC users and is attributable to OCs, we investigated the associations of PLP with metabolites of one-carbon metabolism, tryptophan catabolism, and inflammation in OC users, and evaluated the effects of OCs on these metabolites." | 5.20 | Metabolite profile analysis reveals association of vitamin B-6 with metabolites related to one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in oral contraceptive users and reveals the effects of oral contraceptives o ( Chi, YY; Coats, B; Gregory, JF; Midttun, Ø; Rios-Avila, L; Stacpoole, PW; Ueland, PM, 2015) |
| "PLP is associated with biomarkers of one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in OC users." | 5.20 | Metabolite profile analysis reveals association of vitamin B-6 with metabolites related to one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in oral contraceptive users and reveals the effects of oral contraceptives o ( Chi, YY; Coats, B; Gregory, JF; Midttun, Ø; Rios-Avila, L; Stacpoole, PW; Ueland, PM, 2015) |
| " Evidence has suggested that the activation of indoleamine-2,3-dioxygenase (IDO), the rate-limiting enzyme in the kynurenine pathway (KP), plays a crucial role in inflammation-related diseases." | 3.96 | Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice. ( Boeira, SP; Cattelan Souza, L; Giacomeli, R; Jesse, CR; Prigol, M; Silva, MRP; Zarzecki, MS, 2020) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "A subgroup of individuals with mood and psychotic disorders shows evidence of inflammation that leads to activation of the kynurenine pathway and the increased production of neuroactive kynurenine metabolites." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| " In contrast, schizophrenia and psychosis are hypothesized to arise from increased metabolism of the NMDA receptor antagonist, kynurenic acid (KynA), leading to hypofunction of GABAergic interneurons, the disinhibition of pyramidal neurons and striatal hyperdopaminergia." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Healthy young adults (n = 737) aged 18-28 y without any known diseases or clinical evidence of inflammation provided blood samples for analysis of serum tryptophan/kynurenine metabolites, neopterin, C-reactive protein (CRP), and plasma pyridoxal 5'-phosphate (PLP) with LC-tandem mass spectrometry methodologies." | 3.83 | Serum Immune System Biomarkers Neopterin and Interleukin-10 Are Strongly Related to Tryptophan Metabolism in Healthy Young Adults. ( Brody, LC; Deac, OM; Fan, R; Gardiner, CM; Lu, Z; McCann, A; Meyer, K; Midttun, Ø; Mills, JL; Molloy, AM; Quinn, L; Shane, B; Ueland, PM, 2016) |
| "Median serum CRP and neopterin concentrations were well below established clinical cutoffs for inflammation." | 3.83 | Serum Immune System Biomarkers Neopterin and Interleukin-10 Are Strongly Related to Tryptophan Metabolism in Healthy Young Adults. ( Brody, LC; Deac, OM; Fan, R; Gardiner, CM; Lu, Z; McCann, A; Meyer, K; Midttun, Ø; Mills, JL; Molloy, AM; Quinn, L; Shane, B; Ueland, PM, 2016) |
| "Circulating neopterin and kynurenine/tryptophan ratio (KTR) increase during inflammation and serve as markers of cellular immune activation, but data are sparse on other determinants of these markers and metabolites of the kynurenine pathway." | 3.79 | A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. ( Eussen, SJ; Midttun, Ø; Nygård, O; Tell, GS; Theofylaktopoulou, D; Ueland, PM; Ulvik, A; Vollset, SE, 2013) |
| " In plasma from 3035 patients undergoing coronary angiography for suspected coronary heart disease, we investigated if plasma concentrations of any metabolites in the kynurenine pathway, which depend on PLP as cofactor, may serve as metabolic marker(s) of vitamin B-6 status." | 3.77 | Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. ( Bleie, O; Ebbing, M; Midttun, O; Nilsen, RM; Nygård, O; Ringdal Pedersen, E; Schartum-Hansen, H; Ueland, PM; Ulvik, A, 2011) |
| "Increased oxidative stress (SOX), inflammation and prevalence of cardiovascular disease (CVD) have been reported in end-stage renal disease (ESRD), but their associations with kynurenine (KYN) pathway activation remain unknown." | 3.75 | The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. ( Domaniewski, T; Mysliwiec, M; Pawlak, D; Pawlak, K, 2009) |
| "The kynurenine (KYN) pathway plays an important role in degrading molecules responsible for oxidative stress in the central nervous system (CNS), but can also have neurotoxic effects." | 1.56 | Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease. ( Iwaoka, K; Kato, K; Maeda, T; Otsuka, C; Takahashi, K; Terayama, Y; Yamahara, K, 2020) |
| "Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 1.46 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Iwaoka, K | 1 |
| Otsuka, C | 1 |
| Maeda, T | 1 |
| Yamahara, K | 1 |
| Kato, K | 1 |
| Takahashi, K | 2 |
| Terayama, Y | 1 |
| Zarzecki, MS | 1 |
| Cattelan Souza, L | 1 |
| Giacomeli, R | 1 |
| Silva, MRP | 1 |
| Prigol, M | 1 |
| Boeira, SP | 1 |
| Jesse, CR | 1 |
| Clement, CC | 1 |
| D'Alessandro, A | 1 |
| Thangaswamy, S | 1 |
| Chalmers, S | 1 |
| Furtado, R | 1 |
| Spada, S | 1 |
| Mondanelli, G | 1 |
| Ianni, F | 1 |
| Gehrke, S | 1 |
| Gargaro, M | 1 |
| Manni, G | 1 |
| Cara, LCL | 1 |
| Runge, P | 1 |
| Tsai, WL | 1 |
| Karaman, S | 1 |
| Arasa, J | 1 |
| Fernandez-Rodriguez, R | 1 |
| Beck, A | 1 |
| Macchiarulo, A | 1 |
| Gadina, M | 1 |
| Halin, C | 1 |
| Fallarino, F | 1 |
| Skobe, M | 1 |
| Veldhoen, M | 1 |
| Moretti, S | 1 |
| Formenti, S | 1 |
| Demaria, S | 1 |
| Soni, RK | 1 |
| Galarini, R | 1 |
| Sardella, R | 1 |
| Lauvau, G | 1 |
| Putterman, C | 1 |
| Alitalo, K | 1 |
| Grohmann, U | 1 |
| Santambrogio, L | 1 |
| Wurfel, BE | 1 |
| Drevets, WC | 1 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 1 |
| Morris, HM | 1 |
| Teague, TK | 1 |
| Dantzer, R | 1 |
| Savitz, JB | 1 |
| de Vries, LV | 1 |
| Minović, I | 1 |
| Franssen, CFM | 1 |
| van Faassen, M | 1 |
| Sanders, JS | 1 |
| Berger, SP | 1 |
| Navis, G | 1 |
| Kema, IP | 1 |
| Bakker, SJL | 1 |
| Theofylaktopoulou, D | 1 |
| Midttun, Ø | 4 |
| Ulvik, A | 3 |
| Ueland, PM | 6 |
| Tell, GS | 1 |
| Vollset, SE | 1 |
| Nygård, O | 2 |
| Eussen, SJ | 1 |
| da Silva, VR | 1 |
| Rios-Avila, L | 2 |
| Lamers, Y | 1 |
| Ralat, MA | 1 |
| Quinlivan, EP | 1 |
| Garrett, TJ | 1 |
| Coats, B | 2 |
| Shankar, MN | 1 |
| Percival, SS | 1 |
| Chi, YY | 2 |
| Muller, KE | 1 |
| Stacpoole, PW | 2 |
| Gregory, JF | 2 |
| de Bie, J | 1 |
| Guest, J | 1 |
| Guillemin, GJ | 1 |
| Grant, R | 1 |
| Buras, A | 1 |
| Waszkiewicz, N | 1 |
| Szulc, A | 1 |
| Deac, OM | 1 |
| Mills, JL | 1 |
| Gardiner, CM | 1 |
| Shane, B | 1 |
| Quinn, L | 1 |
| McCann, A | 1 |
| Meyer, K | 1 |
| Fan, R | 1 |
| Lu, Z | 1 |
| Brody, LC | 1 |
| Molloy, AM | 1 |
| Gylling, B | 1 |
| Myte, R | 1 |
| Schneede, J | 1 |
| Hallmans, G | 1 |
| Häggström, J | 1 |
| Johansson, I | 1 |
| Van Guelpen, B | 1 |
| Palmqvist, R | 1 |
| Backhaus, C | 1 |
| Rahman, H | 1 |
| Scheffler, S | 1 |
| Laatsch, H | 1 |
| Hardeland, R | 1 |
| Pawlak, K | 1 |
| Domaniewski, T | 1 |
| Mysliwiec, M | 1 |
| Pawlak, D | 1 |
| Lin, HM | 1 |
| Barnett, MP | 1 |
| Roy, NC | 1 |
| Joyce, NI | 1 |
| Zhu, S | 1 |
| Armstrong, K | 1 |
| Helsby, NA | 1 |
| Ferguson, LR | 1 |
| Rowan, DD | 1 |
| Midttun, O | 1 |
| Ringdal Pedersen, E | 1 |
| Ebbing, M | 1 |
| Bleie, O | 1 |
| Schartum-Hansen, H | 1 |
| Nilsen, RM | 1 |
| Knubel, CP | 1 |
| Martínez, FF | 1 |
| Acosta Rodríguez, EV | 1 |
| Altamirano, A | 1 |
| Rivarola, HW | 1 |
| Diaz Luján, C | 1 |
| Fretes, RE | 1 |
| Cervi, L | 1 |
| Motrán, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TransplantLines Insulin Resistance and Inflammation Biobank and Cohort Study[NCT03272854] | 606 participants (Actual) | Observational [Patient Registry] | 2001-08-31 | Active, not recruiting | |||
| Vitamin B6 Effects on One-Carbon Metabolism[NCT01128244] | Phase 2/Phase 3 | 13 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Vitamin B6 Dependence of One-Carbon Metabolism[NCT00877812] | 45 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography[NCT00354081] | Phase 3 | 3,096 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For all subjects, the concentration of plasma cystathionine in fasting blood samples taken before and after the supplementation period will provide a functional measure of vitamin B6 nutritional status. (NCT01128244)
Timeframe: Fasting blood samples will be taken at baseline and after 28 days of vitamin B6 supplementation.
| Intervention | micromol/L (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Plasma Cystathionine Concentration | 0.14 | 0.13 |
For all subjects, the concentration of plasma pyridoxal phosphate in fasting blood samples taken before and after the supplementation period will provide a direct measure of vitamin B6 nutritional status. (NCT01128244)
Timeframe: Fasting blood samples will be taken at baseline and after 28 days of vitamin B6 supplementation.
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Plasma Pyridoxal Phosphate Concentration | 25.8 | 143 |
Data from analysis of serine, methionine and leucine in the timed blood samples of all subjects will provide a measurement of the metabolic rate of homocysteine remethylation from serine-derived carbon before and after vitamin B6 supplementation. These flux values may be slightly higher than flux of total homocysteine remethylation in Outcome Measure 1 because of the small contribution of methionine salvage to the flux measured in Outcome Measure 2. (NCT01128244)
Timeframe: Blood samples will be taken prior to infusion and at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7.5, and 9h. Infusions will be conducted at baseline and after 28 days
| Intervention | micromol/(kg x hr) (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Homocysteine Remethylation Flux From Serine | 6.60 | 6.92 |
For all subjects, analysis of blood samples before and after vitamin B6 supplementation will allow evaluation of discriminating biomarkers using targeted metabolite profile analysis of one-carbon metabolism and tryptophan catabolism constituents. Also, we will conduct exploratory evaluation and potential identification of new biomarkers using metabolomics analysis on subjects before and after vitamin B6 supplementation. (NCT01128244)
Timeframe: April, 2010 - June, 2014
| Intervention | microl/L (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Secondary Analysis: Plasma 3-hydroxykynurenine Concentration | 25.9 | 27.3 |
Data from analysis of serine, methionine and leucine in the timed blood samples of all subjects will provide a measurement of the metabolic rate of total remethylation of homocysteine before and after vitamin B6 supplementation. (NCT01128244)
Timeframe: Blood samples will be taken prior to infusion and at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7.5, and 9h. Infusions will be conducted at baseline and after 28 days
| Intervention | micromol/(kg x hr) (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Total Homocysteine Remethylation Flux | 6.07 | 5.63 |
1 review available for 3-hydroxykynurenine and Inflammation
| Article | Year |
|---|---|
[Depression and inflammation in rheumatic diseases].
Topics: Cytokines; Depression; Humans; Hypothalamo-Hypophyseal System; Indoleamine-Pyrrole 2,3,-Dioxygenase; | 2016 |
1 trial available for 3-hydroxykynurenine and Inflammation
15 other studies available for 3-hydroxykynurenine and Inflammation
| Article | Year |
|---|---|
Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease.
Topics: Aged; Case-Control Studies; Cytokines; Female; Humans; Inflammation; Interferon-gamma; Interleukin-1 | 2020 |
Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Topics: Animals; Body Weight; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Fem | 2020 |
3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine.
Topics: Animals; Biogenic Amines; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Endothelial Cel | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
The tryptophan/kynurenine pathway, systemic inflammation, and long-term outcome after kidney transplantation.
Topics: Adult; Biomarkers; Chromatography, Liquid; Female; Graft Rejection; Graft Survival; Humans; Inflamma | 2017 |
A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study.
Topics: 3-Hydroxyanthranilic Acid; Aged; Aging; Biomarkers; Body Mass Index; Creatinine; Female; Humans; Inf | 2013 |
Metabolite profile analysis reveals functional effects of 28-day vitamin B-6 restriction on one-carbon metabolism and tryptophan catabolic pathways in healthy men and women.
Topics: Adult; Biomarkers; Creatine; Cystathionine; Female; Humans; Inflammation; Kynurenic Acid; Kynurenine | 2013 |
Central kynurenine pathway shift with age in women.
Topics: Adult; Aged; Aged, 80 and over; Aging; Brain; Female; Humans; Inflammation; Kynurenic Acid; Kynureni | 2016 |
Serum Immune System Biomarkers Neopterin and Interleukin-10 Are Strongly Related to Tryptophan Metabolism in Healthy Young Adults.
Topics: 3-Hydroxyanthranilic Acid; Adolescent; Adult; Biomarkers; Body Mass Index; C-Reactive Protein; Cross | 2016 |
Vitamin B-6 and colorectal cancer risk: a prospective population-based study using 3 distinct plasma markers of vitamin B-6 status.
Topics: Adult; Aged; Biomarkers; Case-Control Studies; Colorectal Neoplasms; Female; Humans; Inflammation; K | 2017 |
NO scavenging by 3-hydroxyanthranilic acid and 3-hydroxykynurenine: N-nitrosation leads via oxadiazoles to o-quinone diazides.
Topics: 3-Hydroxyanthranilic Acid; Acetylcysteine; Aminophenols; Chromatography, Thin Layer; Diazonium Compo | 2008 |
The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease.
Topics: Adult; Age Factors; Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Case-Control Stud | 2009 |
Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease.
Topics: Animals; Chromatography, Liquid; Cluster Analysis; Crohn Disease; Disease Models, Animal; Germ-Free | 2010 |
Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation.
Topics: Adult; Aged; C-Reactive Protein; Coronary Disease; Female; Humans; Inflammation; Kynurenine; Male; M | 2011 |
3-Hydroxy kynurenine treatment controls T. cruzi replication and the inflammatory pathology preventing the clinical symptoms of chronic Chagas disease.
Topics: Animals; Chagas Disease; Chronic Disease; Female; Inflammation; Interferon-gamma; Kynurenine; Mice; | 2011 |